PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
95.27
P/E exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.18. Michael Burry would check for market euphoria. Scrutinize growth expectations.
480.44
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.51. Jim Chanos would check for potential multiple compression risks.
6.70
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.85. Jim Chanos would check for potential asset write-down risks.
-52.00
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -2.95. Seth Klarman would investigate cash flow improvement potential.
31211.22
P/OCF of 31211.22 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
6.70
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.85. Jim Chanos would check for valuation bubble risks.
0.26%
Earnings yield near Drug Manufacturers - Specialty & Generic median of 0.27%. Charlie Munger would verify if industry-standard yields make sense.
-1.92%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.03%. Seth Klarman would investigate cash flow improvement potential.